Table 4 Reduction in V20 (%) using different PTV definitions.
From: A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer
V20 (%) | Absolute V20 (%) and relative (%) reduction in V20 | |||
|---|---|---|---|---|
Patient | PTVroutine | PTVall phases vs. PTVroutine | PTVgating vs. PTVroutine | PTVgating vs. PTVall phases |
1 | 38.0 | 4.1 (10.8%) | 5.1 (13.4%) | 1.0 (2.9%) |
2 | 27.1 | 2.2 (8.1%) | 3.5 (12.9%) | 1.3 (5.2%) |
3 | 29.0 | 2.0 (6.9%) | 2.8 (9.7%) | 0.8 (3.0%) |
4 | 31.0 | 3.8 (12.3%) | 6.7 (21.6%) | 2.9 (10.7%) |
5 | 26.1 | 2.2 (8.4%) | 2.9 (11.1%) | 0.7 (2.9%) |
6 | 28.9 | -1.5 (-5.2%) | 0.1 (0.3%) | 1.6 (5.3%) |
7 | 26.2 | 0.9 (3.4%) | 4.3 (16.4%) | 3.4 (13.4%) |
8 | 20.5 | 3.7 (18%) | 4.4 (21.5%) | 0.7 (4.2%) |
9 | 28.2 | 1.7 (6.0%) | 4.8 (17.0%) | 3.1 (11.7%) |
10 | 27.5 | 4.2 (15.3%) | 6.5 (23.6%) | 2.3 (9.9%) |
11 | 27.6 | 2.4 (8.7%) | 4.9 (17.8%) | 2.5 (9.9%) |
12 | 25.5 | 4.4 (17.3%) | 4.9 (19.2%) | 0.5 (2.4%) |
13 | 28.8 | 2.9 (10.1%) | 6.0 (20.8%) | 3.1 (12.0%) |
14 | 23.9 | 3.7 (15.5%) | 4.2 (17.6%) | 0.5 (2.5%) |
15 | 42.8 | 5.0 (11.7%) | 8.6 (20.1%) | 3.6 (9.5%) |
Mean | 28.7 | 2.8 (9.8%) | 4.6 (16.2%) | 1.9 (7.0%) |
SD | 5.4 | 1.7 (5.9%) | 2.0 (6.0%) | 1.2 (4.1%) |